medigraphic.com

2011, Número 1

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2011; 49 (1)


Inhibidores del sistema renina-angiotensinaaldosterona. Diferencias farmacológicas

Méndez-Durán A

Idioma: Español
Referencias bibliográficas: 31
Paginas: 45-52
Archivo PDF: 47.60 Kb.


RESUMEN

La activación del sistema renina-angiotensina-aldosterona es un mecanismo en cascada que genera hipertensión arterial, cuya estructura ha sido identificada y que actualmente puede ser bloqueada a través de rutas enzimáticas o receptores específicos. La gran diversidad de medicamentos disponibles que actúan en este sistema obliga a seleccionar una sola sustancia. Los inhibidores del sistema renina-angiotensina comparten numerosas características farmacológicas y farmacocinéticas pero no todos son iguales. El conocimiento basado en la evidencia científica permite al clínico elegir el fármaco ideal en cada paciente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Department of Health and Human Services. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2003

  2. European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension J. Hypertens 2003:21(6):1011-1053.

  3. Rosas M, Pastelín G, Martínez J, Herrera-Acosta, Attié F. Hipertensión arterial en México. Guías y recomendaciones para su detección, control y tratamiento. Arch Cardiol Mex 2004;74(2):134-157.

  4. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2003.

  5. Rosas PM, Lara EA, Pastelín HG, Velázquez MO, Martínez RJ, Méndez OA, et al. Re-encuesta Nacional de Hipertensión Arterial (RENAHTA): consolidación mexicana de los factores de riesgo cardiovascular. Cohorte nacional de seguimiento. Arch Cardiol Mex 2005;75(1):96-111.

  6. Unidad de Especialidades Médicas. Estrategia Integral para combatir el sobrepeso, riesgo cardiovascular y diabetes mellitus (SoRiD), en la población mexicana. En: Centro Nacional de Vigilancia Epidemiológica, y Control de Enfermedades, SSa. UNEMEs EC Sobrepeso, RCV y Db M: Un nuevo modelo de atención, Acapulco, México, 3 de abril de 2008. Disponible en http://www. dgepi.salud. gob.mx/eventos/RNE08/MRNE08/5.%20 Panel%20 Metabolicas.pdf

  7. Pérez-Olea J. Historia de la hipertensión arterial. Hipertensión. Boletín Oficial de la Sociedad Chilena de Hipertensión 1997;6(2).

  8. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17:2985-2991.

  9. Weber M. Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999;12(11 Pt 2):139S-147S.

  10. Formica RN Jr, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006;21 (5):1389-1394.

  11. Rump LC. Secondary rise of albuminuria under AT1-receptor blockade- what is the potential role of aldosterone escape? Nephrol Dial Traspl 2007;22(1):5-8.

  12. Yasuda G, Ando D, Hirawa N, Umemura S, Tochikubo O. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Diab Care 2005;28(8):1862-1868.

  13. Galle Jan, Schwedhelm Ed, Pinnetti S, Böger RH, Wanner C. On behalf of the VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23(10):3174-3183.

  14. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009;24(6): 1876-1883.

  15. Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009;151(1):1-10.

  16. Galle Jan, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23(10): 3174-3183.

  17. Weber MA, White WB, Sica D, Bakris GL, Pérez A, Cao C, et al. Antihypertensive efficacy of the novel angiotensin receptor blocker azilsartan medoxomil in combination with amlodipine. J Hypertens 2010;28:e279-e280.

  18. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with Inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Int Med 2008;148(1):38-40.

  19. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010;55(10):976-982.

  20. Sreebhushan R, Rammohan P. Endothelial dysfunctions in patients with essential hypertension: effect of olmesartan vs. telmisartan a randomized, comparative, open label parallel group study. Nephrol Dial Trasplant Plus 2009;2 (Suppl 2):514-521.

  21. Punzi H, Neutel JM, Kereiakes DJ, Shojaee A, Waverczak WF, Dubiel R, Maa JF. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010. [Epub ahead of print].

  22. Burnett JC. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl 1999;17(1);S37-S43.

  23. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin receptor antagonist to reduce blood pressure in patients with treatment resistant hypertension: a randomized, double blind, placebo-controlled trial. Lancet 2009;374(9699):1423-1431.

  24. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensinconverting enzyme inhibition alone. J Am Soc Nephrol 2001;12(10):2051-2059.

  25. Oparil S, Weber MA. Hypertension: a companion to brenner and rector’s. The Kidney. 2th ed. Philadelphia: Elsevier-Saunders;2005.

  26. Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med 2009;151(1):11-20.

  27. Luft FC. Renin inhibition and atherosclerosis. Nephrol Dial Transplant 2008;23(8):2474-2476.

  28. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren conbined with losartan in type 2 diabetes and nephropathy. J Engl J Med 2008;358(23):2433-2446.

  29. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119(4):530-537.

  30. Berl T. Maximizing inhibition of the renin–angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant 2008;23(8):2443-2447.

  31. Parving HH, Brenner BM, McMurray JJV, Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24(5):1663-1671.




2020     |     www.medigraphic.com